Description
This report provides and in-depth analysis of the market for prescription drugs used in the treatment of gastrointestinal (GI) disorders, such as nausea and vomiting, heartburn, gastro-esophageal reflux disease (GERD), ulcer, cancers of the GI tract (colorectal, esophageal, and gastric), Crohn’s disease, ulcerative colitis, irritable bowel syndrome (IBS), diverticular disease, constipation, celiac disease, short bowel syndrome, diarrhea, intestinal obstruction, and digestive enzyme disorders.
For each major segment, the analysis provides an overview of the diseases including epidemiology, a detailed description of products on the market, products in research and development, and market estimates and forecasts through 2010 by drug type and by geographical market (U.S. and non-U.S). Competitive market share information is also provided for 2005 and projected for 2010now and and top drugs. The analysis includes market projections for:
- antiemetics,
- H2 receptorantagonists,
- proton pump inhibitors (PPIs),
- other antacid/antiulcer therapeutics,
- immunotherapy for GI cancers,
- chemotherapy for GI cancers,
- anti-inflammatories,
- anti-spasmodics,
- anti-infectives,
- enzymes, and
- several other miscellaneous GI drug categories
In addition to market data, the report includes current issues and trends affecting the industry and what trends may arise in the future and profiles the top competitors in the field.
The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 100 key industry officials, consultants, health care providers, and government personnel were complied to form the primary basis of information—specifically revenue and market share data—presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
Table of Contents
Chapter One: Executive Summary
- Size and Growth of the Market
- Issues and Trends Affecting the Global Market
Chapter Two: Introduction
- History and Growth of the Industry
- Structure and Organization of the Gastrointestinal Tract
- Gastrointestinal Motility
- Lifetime Gastrointestinal Function
Chapter Three: Antiemetics
- Gastrointestinal Conditions
- Metoclopramide and Other Drugs
Chapter Four: Heartburn, GERD, Ulcer Agents
Description of Products
- Histamine H2-Receptor Antagonists
Research and Development
Market Size and Growth
Competitive Analysis
Chapter Five: Gastrointestinal Cancer Agents
- Gastrointestinal Conditions
- Awaiting Approval and Phase III
Chapter Six: Crohn’s Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments
- Crohn’s Disease and Ulcerative Colitis
- Awaiting Approval and Phase III
Chapter Seven: Other Gastrointestinal Drugs
- Digestive Enzyme Disorders
- Awaiting Approval and Phase III
- Other Product Development Stages
Chapter Eight: Issues and Trends
- Patent Expiration Tactics
- Insurance Coverage Issues
- Smoking and Crohn’s Disease
- Smoking and Ulcerative Colitis
- Dark Chocolate and Diarrhea
Chapter Nine: Total Market Size and Forecast
- Total Market Size and Forecast
Chapter Ten: Corporate Profiles
- Axcan Pharmaceuticals, Inc.
- Bristol-Myers Squibb Company
- Novartis International AG
- Salix Pharmaceuticals, Inc.
- Takeda Chemical Industries, Ltd.
- TAP Pharmaceutical Products, Inc.
Appendix: Company Directory
List of Exhibits
Chapter One: Executive Summary
- Figure 1-1: Market Summary: World Market Prescription Gastrointestinal Drugs 2003-2010
- Table 1-1: Leading Suppliers Significant Segments of Participation, 2005
Chapter Three: Antiemetics
Table 3-1: Estimated U.S. and World Incidence of Nausea and Vomiting by Cause (Chemotherapy and Infectious Disease)
Table 3-2: Currently Available Prescription Antiemetic Agents (Brand Name, Generic Name, Manufacturer, Class)
Table 3-3: Antiemetics in Development (Product, Developer, Phase, Indication, Projected Approval Date)
Table 3-4: World Market for Prescription Antiemetics 2003-2010
Table 3-5: World Market for Prescription Antiemetics (U.S. Revenues vs Non-U.S. Revenues) 2003-2010
Table 3-6: Market for Prescription Antiemetics Leading Suppliers’ Revenues and Market Share 2005 and Projected 2010
Chapter Four: Heartburn, GERD, Ulcer Agents
- Table 4-1: Estimated World and U.S. Incidence of Heartburn/Indigestion (Daily vs Monthly) and Diagnosed GERD
- Table 4-2: Currently Available Prescription Antacid Agents (Brand Name, Generic Name, Manufacturer, Class)
- Table 4-3: Antacids/Antiulcer Agents in Research and Development (Product, Developer, Development Phase, Indication, Projected Approval Date)
- Table 4-4: World Market for Prescription Antacids/Antiulcer Agents 2003-2010
- Table 4-5: World Market Prescription Antacid/Antiulcer Agents by Product Type (H2-Antagonists, Proton Pump Inhibitors, Others) 2003-2010
- Table 4-6: World Market for Prescription Antacids/Antiulcer Agents (U.S. Revenues vs Non-U.S. Revenues) 2003-2010
- Table 4-7: Market for Prescription Antacids/Antiulcer Agents Leading Suppliers’ Revenues and Market Share 2005 and Projected 2010
- Table 4-8: Prescription Antacid/Antiulcer Agents Estimated Revenues and Market Share by Leading Drug 2005
Chapter Five: Gastrointestinal Cancer Agents
- Table 5-1: Estimated U.S. and World Incidence and Mortality of Gastrointestinal Cancers by Type
- Table 5-2: Currently Available Gastrointestinal Cancer Drugs (Brand Name, Generic Name, Manufacturer, Indication)
- Table 5-3: GI Cancer Agents in Research and Development (Product, Developer, Phase, Class, Indication, Projected Approval Date)
- Table 5-4: World Market for Gastrointestinal Cancer Drugs 2003-2010
- Table 5-5: World Market for Gastrointestinal Cancer Drugs by Product Type (Immunotherapy vs Chemotherapy) 2003-2010
- Table 5-6: World Market for Gastrointestinal Cancer Drugs (U.S. Revenues vs Non-U.S. Revenues) 2003-2010
- Table 5-7: Market for Gastrointestinal Cancer Drugs Leading Suppliers’ Revenues and Market Share 2005 and Projected 2010
- Table 5-8: Prescription Antacid/Antiulcer Agents Estimated Revenues and Market Share by Leading Drug 2005
Chapter Six: Crohn’s Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments
- Table 6-1: Estimated World and U.S. Prevalence of Crohn’s Disease, Irritable Bowel Syndrome, and Related Conditions
- Table 6-2: Currently Available Prescription Drugs for Crohn’s, IBS, Ulcerative Colitis, and Related Conditions (Brand Name, Generic Name, Manufacturer, Indication)
- Table 6-3: Antacids/Antiulcer Agents in Research and Development (Product, Developer, Development Phase, Class of Drug, Indication, Projected Approval Date)
- Table 6-4: World Market for Prescription Crohn’s Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments 2003-2010
- Table 6-5: World Market Prescription Crohn’s Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments by Product Type (Anti-inflammatories, Antispasmodics, Others) 2003-2010
- Table 6-6: World Market for Prescription Crohn’s Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments (U.S. Revenues vs Non-U.S. Revenues) 2003-2010
- Table 6-7: Market for Prescription Crohn’s Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments Leading Suppliers’ Revenues and Market Share 2005 and Projected 2010
- Table 6-8: Prescription Crohn’s Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments: Estimated Revenues and Market Share by Leading Drug 2005
Chapter Seven: Other Gastrointestinal Drugs
- Table 7-1: Estimated World and U.S. Incidence of Other GI Conditions (Diarrhia, Giardiasis, Opioid-Induced Constipation, Digestive Enzyme Disortders)
- Table 7-2: Currently Available Prescription Products to Treat Other GI C onditions (Brand Name, Generic Name, Manufacturer, Indication)
- Table 7-3: Other GI Agents in Research and Development (Product, Developer, Development Phase, Drug Class, Indication, Projected Approval Date)
- Table 7-4: World Market for Other Prescription GI Drugs 2003-2010
- Table 7-5: World Market for Other Prescription GI Drugs by Product Type (Anti-Infectives, Enzymes, Others) 2003-2010
- Table 7-6: World Market for Other Prescription GI Drugs (U.S. Revenues vs Non-U.S. Revenues) 2003-2010
- Table 7-7: Market for Prescription Antacids/Antiulcer Agents Leading S uppliers’ Revenues and Market Share 2005 and Projected 2010
Chapter Eight: Issues and Trends
- Table 8-1: Prominent Gastrointestinal Drug Patent Expirations through 2010
Chapter Nine: Total Market Size and Forecast
- Table 9-1: World Market for Prescription Gastronintestinal Drugs 2003-2010
- Table 9-2: World Market Prescription Gastrointestinal Drugs by Product Type, 2003-2010
- Figure 9-1: Trending in the World Market for Prescription Gastrointestinal Drugs by Product Type 2003-2010
- Figure 9-2: World Market Prescription Gastrointestinal Drugs by Percent and Product Type, 2005 Table 9-3: Prescription Gastrointestinal Drugs: Leading Suppliers’ Significant Segments of Participation, 2005
